Table 1.
Drugs and other compounds that regulate ADCD.
Intervention Factors | Mechanism | Mode | Citation |
---|---|---|---|
RCD | – | Normal autophagy | [25, 27] |
Bax/Bak KO | – | [26] | |
SH003 | Activates ATF4 and inhibit G9a | [34] | |
Kaempferol | Activates IRE1-JNK-CHOP and inhibits G9a | [35] | |
Tunicamycin | Promotes ceramide synthesis through GBA1 action | [40] | |
Resveratrol | Activates GBA1 to promote ceramide synthesis | [65] | |
THC | Promotes dihydroceramide accumulation in lysosomes, which leads to LMP | [68] | |
ABTL0812 | Promotes dihydroceramide accumulation, which activates the ATF4-DDIT3-TRIB3 pathway | [71] | |
Loperamide | Activates the ATF4-FAM134B axis and TEX264, leads to lipid accumulation in lysosomes and lipid ROS production | ER-phagy | [36, 47] |
Z36 | Activates FAM134B and the UPR | [37] | |
Sorafenib | Activates FAM134B | [38] | |
Activate smARF | smARF bind to parkin to promote mitophagy | Mitophagy | [58–60] |
AT-101 | Activate BNIP3, BNIP3L and HMOX1 | [61] | |
THPN | TR3 translocation to mitochondrial gap change membrane potential | [62] | |
C18-Pyr-Cer | Activate CerS1/C18-Drp1 | [64] | |
HPV | HPV E7-E2F5-Drp1-ceramide | [69] | |
Inhibition of FLT3-ITD | Activate Drp1-ceramide | [70] | |
Tat-Beclin | Activates Na+-K+ATPase | Autosis | [72] |
Ischemia/Reperfusion | Activates Tfeb and inhibits Rubicon | [74, 75] | |
Tat-Beclin | Beclin1 binds to Na + -K + ATPase | [78] | |
Homocysteine and copper | Activates p22phox and NOX-mediated p62 upregulation | [80] |